RxDoctor Payments Data

Jennifer Degroot

Nurse Practitioner · Sioux Falls, SDNPI 1841500857

Payments from drug & device makers

$1,701in general payments, 2019–2025

Across 73 payments — averaging $23.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$719
  • AstraZeneca$229
  • GSK$160
  • Novo Nordisk$108
  • Grifols USA, LLC$94
  • Inspire Medical Systems, Inc.$84
  • plus $308 from 12 others

What the payments were for

  • Travel & lodging$37122%
  • Food & beverage$1,31377%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,701 in reported general payments places this provider in the 85th percentile of 504 nurse practitioner providers in South Dakota.

See all nurse practitioner providers in South Dakota

Medicare billing

Part B allowed, 2024
$9,158
Medicare patients
130
Services billed
147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter135$96,694
Breo ElliptaFluticasone/Vilanterol40$19,134
Invega SustennaPaliperidone Palmitate12$14,394
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$11,432
Incruse ElliptaUmeclidinium Bromide22$9,835
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$6,473
Advair HfaFluticasone Propion/Salmeterol13$5,848
Albuterol Sulfate HfaAlbuterol Sulfate104$3,430
Fluticasone-SalmeterolFluticasone Propion/Salmeterol37$2,631
Ventolin HfaAlbuterol Sulfate11$734
Montelukast Sodium65$386
Fluticasone Propionate17$370
Prednisone66$309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$160$125,663197 claims
AstraZenecaBreztri Aerosphere$229$11,43217 claims
Boehringer IngelheimStiolto Respimat$42$6,47312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 504 nurse practitioner providers in South Dakota.

Other nurse practitioner in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →